Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss
By
kfftiffanyf
June 29, 2026
Clinical Scorecard: Approximately 3.8 Million Medicare Recipients May Qualify for the New Temporary GLP-1 Bridge Program for Weight Loss Medications
At a Glance
Category Detail
Condition Obesity and Overweight Management Key Mechanisms GLP-1 receptor agonists for weight reduction Target Population Medicare beneficiaries with specific BMI criteria Care Setting Medicare Part D coverage
Key Highlights
3.8 million Medicare beneficiaries eligible for GLP-1 Bridge program Program covers Wegovy, Zepbound, and Foundayo for weight management Eligibility based on BMI and absence of certain comorbid conditions Program runs from July 1, 2026, to December 2027 Estimated costs to Medicare range from $1.3 billion to $10 billion based on participation Guideline-Based Recommendations
Diagnosis
Eligibility requires a BMI of 35 or more, or BMI of 27 or more with comorbid conditions Management
Coverage limited to beneficiaries without conditions treated by GLP-1 drugs under Part D Monitoring & Follow-up
Participation rates and prescription fills will impact program costs Risks
Limited eligibility may exclude many Medicare beneficiaries with obesity or overweight Patient & Prescribing Data
Medicare Part D enrollees meeting clinical criteria
Eligibility excludes those who have filled GLP-1 prescriptions in 2026
Clinical Best Practices
Assess BMI and comorbid conditions for eligibility Monitor participation and prescription fill rates for cost management Related Resources & Content
